E-LIB Suche - Ergebnisse für: Katja Weisel

1

International Myeloma Working Group immunotherapy committee..:

Rodriguez-Otero, Paula ; Usmani, Saad ; Cohen, Adam D...
The Lancet Oncology. 25 (2024) 5 - p. e205-e216 , 2024

Link: https://doi.org/10.1016/..

2

Comparative Efficacy of Talquetamab vs. Current Treatments ..:

Einsele, Hermann ; Moreau, Philippe ; Bahlis, Nizar...
Advances in Therapy. 41 (2024) 4 - p. 1576-1593 , 2024

Link: https://doi.org/10.1007/..

3

Daratumumab for patients with myeloma with early or late re..:

Spencer, Andrew ; Moreau, Philippe ; Mateos, Maria-Victoria...
Blood Advances. 8 (2024) 2 - p. 388-398 , 2024

Link: https://doi.org/10.1182/..

4

Cytomegalovirus immunoglobulin serology prevalence in patie..:

Salwender, Hans ; Weinhold, Niels ; Benner, Axel...
Hematology. 29 (2024) 1 - p. , 2024

Link: https://doi.org/10.1080/..

5

The Phase 2 Cartitude-2 Trial: Updated Efficacy and Safety ..:

Hillengass, Jens ; Cohen, Adam D. ; Agha, Mounzer...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S36-S37 , 2024

Link: https://doi.org/10.1016/..

6

Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide..:

Oriol, Albert ; Dimopoulos, Meletios ; Schjesvold, Fredrik...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) 3 - p. 165-176.e4 , 2024

Link: https://doi.org/10.1016/..

7

Safety and efficacy of belantamab mafodotin with pembrolizu..:

Suvannasankha, Attaya ; Bahlis, Nizar ; Trudel, Suzanne...
Cancer. , 2024

Link: https://doi.org/10.1002/..

8

Belantamab mafodotin: an important treatment option for vul..:

Mateos, Maria Victoria ; Weisel, Katja ; Terpos, Evangelos...
Haematologica. , 2024

Link: https://doi.org/10.3324/..

9

Hemophagocytic lymphohistiocytosis and macrophage activatio..:

Ruffer, Nikolas ; Kosch, Ricardo ; Weisel, Katja..
Zeitschrift für Rheumatologie. 83 (2024) 5 - p. 376-386 , 2024

Link: https://doi.org/10.1007/..

10

Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multi..:

Seckinger, Anja ; Salwender, Hans ; Martin, Hans...
International Journal of Molecular Sciences. 25 (2024) 12 - p. 6431 , 2024

Link: https://doi.org/10.3390/..

11

Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenal..:

Weisel, Katja ; Dimopoulos, Meletios A. ; Beksac, Meral...
Leukemia & Lymphoma. 65 (2024) 4 - p. 481-492 , 2024

Link: https://doi.org/10.1080/..

12

Characterization and Outcomes of Spanish Patients With Rela..:

Mateos, Maria-Victoria ; Weisel, Katja ; Diels, Joris...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) 4 - p. 224-231.e2 , 2024

Link: https://doi.org/10.1016/..

13

P-087 Characterization of minimal residual disease (MRD) in..:

Touzeau, Cyrille ; Weisel, Katja ; Bahlis, Nizar...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S82-S83 , 2023

Link: https://doi.org/10.1016/..

14

P-052 LINKER-MM3, a phase 3, open-label, randomized study o..:

Weisel, Katja ; Hungria, Vania ; Quach, Hang...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S63-S64 , 2023

Link: https://doi.org/10.1016/..

15

P-282 Ranking importance of prognostic factors for relapsed..:

Kumar, Shaji ; Leleu, Xavier ; Weisel, Katja...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S191-S192 , 2023

Link: https://doi.org/10.1016/..